Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company focused on treating primary and metastatic liver cancers. Its lead product candidate is HEPZATO KIT for administering high-dose chemotherapy to the liver while controlling systemic exposure. The company has a clinical trial program investigating objective response rate in metastatic uveal melanoma.
Overview
Strengths
- ROIC of 20.1% beats 88% of its 51 Medical Devices peers (median 9.6%).
- Improving fundamentals over the last year: return on assets up 36.6 points, gross margin up 2.8 points and asset turnover up 41.9%.
- Cheaper than its own history: P/FCF 24.0x vs. a historical average of 86.7x.
Weaknesses
- Shareholder dilution: the share count has grown by 51.1% a year over the last three years.
- Unreliable cash generation: free cash flow was negative in 5 of the last 6 years.
- Our discounted cash flow target price (3.51 USD) is 76% below the current price.
- Unstable profitability: operating margin ranged from -1,849% to 1% over the last 6 years, with operating losses in 5 of them.
Key Financial Data